Churchill Capital Vi's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Churchill Capital Vi (CCVI) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Churchill Capital Vi vs. its Competitors, Q3 2023
Net income growth, year on year
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Churchill Capital Vi and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Churchill Capital Corp Vi | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Churchill Capital Vi's competitor groups requires a Commercial License.
Churchill Capital Vi's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Churchill Capital Corp Vi | - | - | - | Yes |
| Competitors combined (2) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CCVI Stock Performance relative to its Competitors
Publicly Traded Peers of Churchill Capital Corp Vi
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Churchill Capital Corp Vi | 288.44 | - |
| Bellevue Life Sciences Acquisition Corp | 247.59 | 1.81 |
| Ix Acquisition Corp | - | - |
| SUBTOTAL | 536.03 | 1.81 |
Sources: Churchill Capital Corp Vi's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Churchill Capital Corp Vi versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Churchill Capital Vi's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Churchill Capital Corp Vi | 288 | - | - |
| Bellevue Life Sciences Acquisition Corp | 248 | - | - |
| Ix Acquisition Corp | - | - | - |
| PEERS TOTAL | 248 | - | - |
Churchill Capital Vi's Valuation vs Competitive Position
Valuation multiples vs the Blank Checks industry average (68 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 50.9x | 45.2x | +5.7x |
| EV / EBITDA | 18.1x | 26.4x | -8.3x |
| P/B | -12.3x | 6.7x | -19.0x |
| Return on Equity | -45.18 % | industry aggregate | -59.35 % |
| Return on Invested Capital | -0.51 % | 0.96 % (avg) | -1.47 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Churchill Capital Vi's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 59.4 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- Industry revenue growing at a healthy 27.5% median pace.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Churchill Capital Vi's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Churchill Capital Corp Vi | 0.34 | 0.40 | - |
| Bellevue Life Sciences Acquisition Corp | 0.11 | 0.18 | 0.02 |
| Ix Acquisition Corp | 0.03 | 0.06 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Churchill Capital Vi's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Churchill Capital Corp Vi | Q3 2023 | - | -71.2 % |
| Bellevue Life Sciences Acquisition Corp | Q2 2026 | -69.4 % | - |
| Ix Acquisition Corp | Q2 2026 | - | - |
| PEERS TOTAL | -69.4 % | +99.9 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Churchill Capital Vi's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Churchill Capital Corp Vi | Q3 2023 | - | - |
| Bellevue Life Sciences Acquisition Corp | Q2 2026 | -77.1 % | - |
| Ix Acquisition Corp | Q2 2026 | - | - |
Churchill Capital Vi's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Churchill Capital Corp Vi | 2.49% | 2.51% | - |
| Bellevue Life Sciences Acquisition Corp | - | - | - |
| Ix Acquisition Corp | 20.32% | 48.91% | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Churchill Capital Vi's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Churchill Capital Corp Vi | 51.19 | - |
| Bellevue Life Sciences Acquisition Corp | - | 136.88 |
| Ix Acquisition Corp | - | - |
| PEERS AVERAGE | - | 296.35 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.